Key clinical point: High KPNA2 expression is associated with increased risk of death in clear cell and papillary renal cell carcinoma (RCC).
Major finding: Survival was poorer for patients with clear cell RCC having high KPNA2 protein levels (74 vs. 171 months) or mRNA levels (hazard ratio for death, 1.45) and for patients with papillary RCC having high KPNA2 mRNA levels (HR, 6.2).
Study details: A retrospective dual cohort study of 240 clinic patients and 771 Cancer Genome Atlas patients.
Disclosures: The authors reported that they had no conflict of interests.
Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008